Gardella Thomas J, Vilardaga Jean-Pierre
Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts (T.J.G.); and Laboratory for GPCR Biology, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (J.-P.V.)
Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts (T.J.G.); and Laboratory for GPCR Biology, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (J.-P.V.).
Pharmacol Rev. 2015;67(2):310-37. doi: 10.1124/pr.114.009464.
The type-1 parathyroid hormone receptor (PTHR1) is a family B G protein-coupled receptor (GPCR) that mediates the actions of two polypeptide ligands; parathyroid hormone (PTH), an endocrine hormone that regulates the levels of calcium and inorganic phosphate in the blood by acting on bone and kidney, and PTH-related protein (PTHrP), a paracrine-factor that regulates cell differentiation and proliferation programs in developing bone and other tissues. The type-2 parathyroid hormone receptor (PTHR2) binds a peptide ligand, called tuberoinfundibular peptide-39 (TIP39), and while the biologic role of the PTHR2/TIP39 system is not as defined as that of the PTHR1, it likely plays a role in the central nervous system as well as in spermatogenesis. Mechanisms of action at these receptors have been explored through a variety of pharmacological and biochemical approaches, and the data obtained support a basic "two-site" mode of ligand binding now thought to be used by each of the family B peptide hormone GPCRs. Recent crystallographic studies on the family B GPCRs are providing new insights that help to further refine the specifics of the overall receptor architecture and modes of ligand docking. One intriguing pharmacological finding for the PTHR1 is that it can form surprisingly stable complexes with certain PTH/PTHrP ligand analogs and thereby mediate markedly prolonged cell signaling responses that persist even when the bulk of the complexes are found in internalized vesicles. The PTHR1 thus appears to be able to activate the Gα(s)/cAMP pathway not only from the plasma membrane but also from the endosomal domain. The cumulative findings could have an impact on efforts to develop new drug therapies for the PTH receptors.
1型甲状旁腺激素受体(PTHR1)是B族G蛋白偶联受体(GPCR),可介导两种多肽配体的作用;甲状旁腺激素(PTH),一种内分泌激素,通过作用于骨骼和肾脏来调节血液中钙和无机磷酸盐的水平;以及甲状旁腺激素相关蛋白(PTHrP),一种旁分泌因子,可调节发育中的骨骼和其他组织中的细胞分化和增殖程序。2型甲状旁腺激素受体(PTHR2)结合一种名为tuberoinfundibular peptide - 39(TIP39)的肽配体,虽然PTHR2/TIP39系统的生物学作用不如PTHR1明确,但它可能在中枢神经系统以及精子发生中发挥作用。通过各种药理学和生化方法探索了这些受体的作用机制,所获得的数据支持一种基本的“双位点”配体结合模式,现在认为B族肽激素GPCR均采用这种模式。最近对B族GPCR的晶体学研究提供了新的见解,有助于进一步完善整体受体结构和配体对接模式的细节。关于PTHR1的一个有趣的药理学发现是,它可以与某些PTH/PTHrP配体类似物形成惊人稳定的复合物,从而介导明显延长的细胞信号反应,即使当大部分复合物存在于内化囊泡中时这种反应仍会持续。因此,PTHR1似乎不仅能够从质膜激活Gα(s)/cAMP途径,还能从内体结构域激活该途径。这些累积的发现可能会对开发针对PTH受体的新药物疗法的努力产生影响。